...
首页> 外文期刊>Journal of Medicine, Physiology and Biophysics >The Efficacy of Ivabradine Alone, Metoprolol Alone and Combination of Ivabradine and Metoprolol in Reducing Heart Rate Among Patients Undergoing Computed Tomography Coronary Angiography
【24h】

The Efficacy of Ivabradine Alone, Metoprolol Alone and Combination of Ivabradine and Metoprolol in Reducing Heart Rate Among Patients Undergoing Computed Tomography Coronary Angiography

机译:电脑断层扫描冠状动脉造影患者中单独使用伊伐布雷定,单独使用美托洛尔和联合使用伊伐布雷定和美托洛尔降低心率的疗效

获取原文
           

摘要

Objectives : to determine the efficacy of Ivabradine alone, Metoprolol alone and Combination of Ivabradine and Metoprolol in reducing heart rate among patients undergoing Computed Tomography Coronary Angiography (CTCA). Methodology : it was a randomized controlled trial comprised of 200 patients. Patients undergoing CTCA having heart rates greater than 80 bpm were divided into three groups. Group A was given Ivabradine and a placebo, Group B received Metoprolol and placebo while Group C was administered with Ivabradine and Metoprolol an hour prior to the scan. The scan was carried under similar situations. Heart rate and variability was recorded before and during the scan. Results : The mean heart rate variability and mean reduction in heart rate of Group A was 3.13±1.01 and 19.02±2.05 respectively. The mean heart rate variability and mean reduction in heart rate of Group B was 4.27±1.08 and 12.11±2.45 respectively. While, the mean heart rate variability and mean reduction in heart rate of Group C was 1.88±0.42 and 25.03±2.74 respectively. Conclusion : Ivabradine is an effective and safe drug for reducing heart rate in patients having CTCA, especially among patients who are unable to tolerate calcium channel blockers and beta blockers owing to their side effects.
机译:目的:确定在计算机断层扫描冠状动脉造影(CTCA)患者中,单独使用伊伐布雷定,单独使用美托洛尔以及联合使用伊伐布雷定和美托洛尔降低心率的疗效。方法:这是一项包括200名患者的随机对照试验。接受CTCA且心率大于80 bpm的患者分为三组。扫描前一个小时,给A组服用伊伐布雷定和安慰剂,B组接受美托洛尔和安慰剂,而C组则给予伊伐布雷定和美托洛尔。扫描是在类似情况下进行的。在扫描之前和期间记录心率和变异性。结果:A组的平均心率变异性和平均心率降低分别为3.13±1.01和19.02±2.05。 B组的平均心率变异性和平均心率降低分别为4.27±1.08和12.11±2.45。而C组的平均心率变异性和平均心率降低分别为1.88±0.42和25.03±2.74。结论:伊伐布雷定是降低CTCA患者心率的有效且安全的药物,尤其是由于副作用而不能耐受钙通道阻滞剂和β受体阻滞剂的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号